SOLTF (Nxera Pharma Co) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


SOLTF Nxera Pharma Co Ltd SOLTF
84 GF Score
Price $6.37
GF Value $7.77
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nxera Pharma Co's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SOLTF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Margin of Safety % (DCF Earnings Based) falls into.


SOLTF
84GF Score
Nxera Pharma Co Ltd SOLTF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $6.37 is trading 18% below its estimated GF Value™ of $7.77. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $7.77 vs. price of $6.37 (18% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Other Exchanges 4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score

Get the complete analysis for SOLTF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.37
Price
$7.77
GF Value